Disease · MONDO_0040679

urothelial carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. urothelial carcinoma. Diseases, record MONDO_0040679. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0040679

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: urothelial carcinoma; Open Targets
Open Targets ID: MONDO_0040679; Open Targets
Other names: Uroepithelial carcinoma, transitional cell car. -uroth., transitional cell carcinoma of the urinary tract, transitional cell carcinoma of the urothelial tract; Open Targets
NCI Thesaurus: C4030; NCI Thesaurus
Highest stage of its drugs: Approval, for 8 of its 185 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs185

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Approval	ClinicalTrials.gov, DailyMed and TTD	32	29	29	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Approval	DailyMed	28	26	26	Drugs and targets
ENFORTUMAB VEDOTIN	CHEMBL3301589	Antibody drug conjugate	Approval	ClinicalTrials.gov and TTD	21	20	20	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Approval	TTD	11	10	10	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Approval	TTD	10	9	8	Drugs and targets
SACITUZUMAB GOVITECAN	CHEMBL3545262	Antibody drug conjugate	Approval	TTD	6	5	5	Drugs and targets
ERDAFITINIB	CHEMBL3545376	Small molecule	Approval	DailyMed, FDA and PMDA	7	3	3	Drugs and targets
ENFORTUMAB	CHEMBL3301579	Antibody	Approval	TTD	1	0	0	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	49	49	49	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	40	40	40	Drugs and targets

1 to 10 of 185

See all 185 drugs

Targets196

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FGFR3	Fibroblast growth factor receptor	10	Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 1 antagonist; Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	10	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	10	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
FGFR1	Fibroblast growth factor receptor	9	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2260	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	9	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
TUBA1A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 196

See all 196 targets

Trials286

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02807636	Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	Phase 3	1,213	2023-12-13	Urothelial Carcinoma	ATEZOLIZUMAB, CARBOPLATIN, CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT02853305	Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)	Phase 3	1,010	2021-05-20	Urothelial Carcinoma Associated 1 RNA, Human	CARBOPLATIN, CISPLATIN, GEMCITABINE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02928406	A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract	Phase 3	1,004	2024-04-04	Urinary Tract Cancer	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02302807	A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]	Phase 3	931	2018-04-11	Bladder Cancer	ATEZOLIZUMAB, DOCETAXEL, PACLITAXEL, VINFLUNINE	Its record names the disease	ClinicalTrials.gov
NCT02450331	A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection	Phase 3	809	2020-11-18	Carcinoma, Transitional Cell	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03390504	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations	Phase 3	629	2025-05-14	Urothelial Cancer	ERDAFITINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors	Phase 1/2	557	2023-03-13	Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer	BEMPEGALDESLEUKIN, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02426125	A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer	Phase 3	530	2019-03-08	Urothelial Carcinoma	DOCETAXEL, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT01631552	Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer	Phase 1/2	515	2021-04-06	Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer	SACITUZUMAB GOVITECAN	Its record names the disease	ClinicalTrials.gov
NCT00942331	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	Phase 3	506	2020-02-17	Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma	BEVACIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 286

See all 286 trials

Comparisons in its trials87

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: deaths from any cause	393 of 443	379 of 459	902	NCT02302807	Trial comparisons
Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: serious adverse events	189 of 443	192 of 459	902	NCT02302807	Trial comparisons
OBSERVATION vs ATEZOLIZUMAB: deaths from any cause	162 of 403	171 of 406	809	NCT02450331	Trial comparisons
OBSERVATION vs ATEZOLIZUMAB: serious adverse events	72 of 398	122 of 390	788	NCT02450331	Trial comparisons
Ramucirumab + Docetaxel vs Placebo+Docetaxel: deaths from any cause	193 of 258	209 of 265	523	NCT02426125	Trial comparisons
Ramucirumab + Docetaxel vs Placebo+Docetaxel: serious adverse events	111 of 258	107 of 265	523	NCT02426125	Trial comparisons
Arm II (GCB) vs Arm I (GCP): deaths from any cause	207 of 252	216 of 254	506	NCT00942331	Trial comparisons
Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo: Number of Participants Who Discontinue Study Treatment Due to an AE	83 of 241	44 of 242	483	NCT03898180	Trial comparisons
Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo: Number of Participants Who Experience an AE	234 of 241	235 of 242	483	NCT03898180	Trial comparisons
Arm II (GCB) vs Arm I (GCP): Number of Patients Experiencing Grade 3+ Toxicity	183 of 237	163 of 232	469	NCT00942331	Trial comparisons

1 to 10 of 87

See all 87 comparisons in its trials

Papers from its trials233

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38849479	RESULT	1	PubMed
37778952	RESULT	1	PubMed
37410476	RESULT	1	PubMed
37236636	RESULT	1	PubMed
36463732	RESULT	1	PubMed
32946924	RESULT	1	PubMed
32945632	RESULT	1	PubMed
32645282	RESULT	1	PubMed
32360052	RESULT	1	PubMed
31702432	RESULT	1	PubMed

1 to 10 of 233

See all 233 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0040679

GET https://conductscience.org/api/diseases/v1/MONDO_0040679/drugs?page=2

API reference For AI assistants